2024P001014 Phase I
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
15 results
24-414 Phase II
A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
24-317 Phase II
A Phase 2 trial of emapalumab for the prevention of CAR-T cell associated toxicities
18-604 Phase II
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2).
20-518 Phase I
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
23-474 Phase I
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
22-533 Phase II
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
24-209 Phase II
EVEREST-2: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
24-446 N/A
Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release
21-072 N/A
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Showing 1 - 10 of 15 results